C
Caroline Speers
Researcher at BC Cancer Agency
Publications - 181
Citations - 7615
Caroline Speers is an academic researcher from BC Cancer Agency. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 37, co-authored 164 publications receiving 6791 citations. Previous affiliations of Caroline Speers include University of British Columbia.
Papers
More filters
Journal ArticleDOI
Metastatic Behavior of Breast Cancer Subtypes
Hagen F. Kennecke,Rinat Yerushalmi,Ryan Woods,Maggie C.U. Cheang,David Voduc,Caroline Speers,Torsten O. Nielsen,Karen A. Gelmon +7 more
TL;DR: Breast cancer subtypes are associated with distinct patterns of metastatic spread with notable differences in survival after relapse, and luminal/HER2 and HER2-enriched tumors were associated with a significantly higher rate of brain, liver, and lung metastases.
Journal ArticleDOI
Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer
Ivo A. Olivotto,Chris Bajdik,Peter M. Ravdin,Caroline Speers,Andrew J. Coldman,B. Norris,Greg J. Davis,Stephen Chia,Karen A. Gelmon +8 more
TL;DR: Adjuvant! performed reliably, but patients younger than age 35 or with known additional adverse prognostic factors such as LVI require adjustment of risks to derive reliable predictions of prognosis without adjuvant systemic therapy and the absolute benefits of adjuant systemic therapy.
Journal ArticleDOI
The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer
Stephen Chia,Caroline Speers,Yulia D'yachkova,Anna Kang,Suzanne Malfair-Taylor,Jeff Barnett,Andy Coldman,Karen A. Gelmon,Susan E. O'Reilly,Ivo A. Olivotto +9 more
TL;DR: This study characterized the use and assessed the impact on survival of population‐based access to new agents for the treatment of MBC.
Journal ArticleDOI
Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer
Caroline A. Lohrisch,Charles Paltiel,Karen A. Gelmon,Caroline Speers,Suzanne C. Malfair Taylor,Jeff Barnett,Ivo A. Olivotto +6 more
TL;DR: It is suggested that adjuvant chemotherapy is equally effective up to 12 weeks after definitive surgery but that RFS and OS appear to be compromised by delays of more than 12 weeks following definitive surgery.
Journal ArticleDOI
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
Stephen Chia,B. Norris,Caroline Speers,Maggie C.U. Cheang,Blake Gilks,Allen M. Gown,David G. Huntsman,Ivo A. Olivotto,Torsten O. Nielsen,Karen A. Gelmon +9 more
TL;DR: Larger studies are needed to more clearly define the prognostic impact of HER2 in tumors